Skip to main content

LFA Collective Data Analysis Initiative

Developing new, safe, effective therapies for lupus is incredibly complex. In clinical trials, researchers face many obstacles that make it very difficult to show whether a potential treatment works or is better than the current treatment.

The goal of the Lupus Foundation of America's Collective Data Analysis Initiative (LFA CDAI) is to improve clinical trial design so new treatments can get to people who need them faster.

The LFA CDAI began in 2009 as a unique collaboration among multiple companies with a shared goal: to get new treatments to people with lupus.

LFA CDAI combines data from past lupus studies from around the world. LFA CDAI biostatisticians analyze the data to identify trends and gain new insights. The results help the entire lupus research community conduct clinical trials that produce more meaningful data. 

To date, LFA-CDAI has collected data from 10 different trials and published more than 13 abstracts and publications.

For more information on the LFA CDAI, please contact research@lupus.org.

Publications

Longitudinal Patterns of Response to Standard of Care Therapy for Systemic Lupus Erythematosus: Implications for Clinical Trial Design

Mimi Kim,Joan Merrill, Kenneth Kalunian, Bevra Hahn, Anita Roach, and Peter Izmirly, for the Lupus Foundation of America Collective Data Analysis Initiative Group

Download PDF


Impact of standard of care treatments and disease variables on outcomes in systemic lupus erythematosus trials: analysis from the Lupus Foundation of America Collective Data Analysis Initiative

Kenneth Carekin Kalunian, Mimi Kim, Xianhong Xie, Amrutha Baskaran, Rossi Paola Daly, Joan Tenenbaum Merrill

Download PDF

Abstracts

Missing Outcomes in SLE Clinical Trials: Impact on Estimating Treatment Effects

Mimi Kim, Joan T. Merrill, Kenneth C. Kalunian, Leslie Hanrahan and Peter M. Izmirly.

Read the abstract


Initial Results for the LFA Collective Data Analysis Initiative (LFA CDAI): How Do Subjects From Lupus Clinical Trials Randomized to Standard of Care Respond Over Time?

Kalunian, Kenneth C., Kim, Mimi, Hanrahan, Leslie M., Becker, Jean-Claude P., Bongardt, Sabine, Brunetta, Paul, et al. Arthritis Rheum 2011;63 Suppl 10 :2255.

Read the abstract


Impact of Baseline Disease Severity and Treatments on Outcomes in Clinical Trials of SLE: Results from the SOCCIT Program.

Kalunian, Kenneth C., Kim, Mimi, Behrens, Timothy W., Bongardt, Sabine, Brunetta, Paul, Daly, Paola, et al. Arthritis Rheum 2013;65 Suppl 10 :1808. 


FRI0384 Background Treatment and Disease Variables Affecting High Placebo Responses in Systemic  Lupus Erythematosus (SLE) Trials: Update from the SOCCIT Program. [abstract]

Kalunian, Kenneth C., Kim, Mimi, Baskaran, Amrutha, Daly, Paola, Merrill, Joan T. Ann Rheum Dis 2014;73(Suppl2): 526

Read the abstract


FRI0384 Background Treatment and Disease Variables Affecting High Placebo Responses in Systemic  Lupus Erythematosus (SLE) Trials: Update from the SOCCIT Program. [abstract]

Kalunian, Kenneth C., Kim, Mimi, Baskaran, Amrutha, Daly, Paola, Merrill, Joan T. EULAR 2014  

Read the abstract


Longitudinal Patterns of Response to Standard of Care Therapy for Systemic Lupus Erythematosus: Implications for Clinical Trial Design

Kim, M., Merrill, J., Kalunian, K., Hahn, B., Roach, A., Izmirly, P.

Presented at:

  • EULAR 2016 Conference, London, 6/16
  • LUPUS 2016 Conference, Armonk, 9/16
  • ACR 2016 Conference, Washington DC, 11/16

Read the abstract


Estimating Duration of Response in Systemic Lupus Erythematosus (SLE) Trials [abstract]

Kim M, Merrill JT, Kalunian KC, Hanrahan L, Izmirly PM. Arthritis Rheumatol. 2017; 69 (suppl 10).

Read the abstract

Lectures

Kalunian, K. (2013, October). Impact of Baseline Disease Severity and Treatments on Outcomes in Clinical Trials of SLE: Results from the SOCCIT Program. Lecture given at American College of Rheumatology 2014 Annual Meeting in San Diego Convention Center, San Diego.


Izmirly, P.  (2016, November) Longitudinal Patterns of Response to Standard of Care Therapy for Systemic Lupus Erythematosus: Implications for Clinical Trial Design. Lecture given at American College of Rheumatology 2016 Annual Meeting in Washington DC.

Read the abstract


Kim, M. (2016, September) Novel Clinical Trial Designs in Lupus.  Lecture given at Lupus 2016 Conference in Armonk, NY. 


Kim, M., Merrill, J., Kalunian, K., Hahn, B., Roach, A., Izmirly, P. (2017, November)  Longitudinal Patterns of Response to Standard of Care Therapy for Systemic Lupus Erythematosus: Implications for Clinical Trial Design. Arthritis and Rheumatism. Lecture will be given at American College of Rheumatology 2017 Annual Meeting at the San Diego Convention Center, San Diego. 

Read the abstract